



## **Journal of Global Pharma Technology**

Available Online at: www.jgpt.co.in

RESEARCH ARTICLE

Synthesis, Characterization and Biological Study of the Ligand 2-methyl-5-[(2E)-2-(4-Nitrobenzylidene) Hydrazinyl]- 1, 3, 4-Oxadiazole with some of its Transition Metal Complexes

Zainab M. Kareem, Ibrahim. A. Flifel, Ahmed H. Mohammed


University of Thi-Qar / Science College/ Iraq.

#### Abstract

A new series of transition metal ions (Cr (III), Co (III), Cu (II) and Ni (II) complexes with the ligand 2-methyl-5-[(2E)-2-(4-nitrobenzylidene) hydrazinyl]-1, 3, 4-oxadiazole were synthesized. A ligand was synthesized by reaction hydrazine hydrate with ethyl acetate in ethanol as solvent, the product reaction with potassium hydroxide and carbon disulphide to give 5-methyl-1,3,4-oxadiazole-2-thaiol, the product was reacted with hydrazine hydrate again to produce 2-hydrazinyl-5-methyl-1,3,4-oxadiazol. The resultant was mixed with parnitro-benzldehyde to produce the ligand (L2). The newly synthesized compounds were characterized by Fourier transform infrared (FTIR) Spectroscopy, Nuclear Magnetic Resonance Spectroscopy (1H NMR), elemental analyses (C, H, N), Mass Spectra data. The program Hyperchem 7.51 have been used for theoretical calculation using PM3 method to study the electrostatic potential, electron density, heat of complexation. It has been shown through all the above diagnostic measures that ligand is formed with the (Cu, Co and Ni) ions tetrahedral complexes and with the Cr formed octahedral complex. The biological study of ligand and its complexes showed that all prepared compounds have antibacterial against three types of bacteria and there was high percentage of hemolysis.

**Keyword**: 1, 3, 4-Oxadiazole derivative, Antibacterial, Hyperchem, Hemolysis.

#### Introduction



A Cyclic organic compound containing all atoms in ring formation is named a carboxylic compound. If at least one atom other than carbon forms a part of the ring designated as a hetro system compound. The most common hetro atoms are sulfur, nitrogen and oxygen [1]. 1,3,4-Oxadiazole is a heterocyclic compound containing an oxygen atom and two nitrogen atoms in a five membered ring. It is derived from furan by substitution of two methine groups (=CH) with two pyridine type nitrogen's (-N=) [2, 3]. At room temperature it is liquid in nature and having boiling point at 150°C. 1, 3, 4-oxadiazole have good thermal stability [4]. There are three other known isomers for 1,3,4 oxadiazole, namely; 1,2,4-oxadiazole 1,2,3-oxadiazole and 1,2,5oxadiazole.

However; 1,3,4-oxadiazole and 1,2,4oxadiazole are better known, and more widely studied by researchers [5]. The 1,3,4oxadiazole-derivatives are the most stable among the oxadiazole isomers and attracted considerable attention and became important construction motif for the development of new drugs.Compounds containing 1,3,4-oxadiazole cores have a broad biological activity spectrum including antibacterial [6], antifungal [7], analgesic [8], anti-inflammatory [9], antiviral anticancer [11], antihypertensive [12] and anticonvulsant [13]. The ability of 1, 3, 4oxadiazoles to undergo various chemical reactions has made them important for molecule planning because of their privileged structure, which has enormous biological potential [14].

#### **Experimental**

## Preparation Method of Ligand (L2)

Ethyl acetate (0.1 mol, 8.8 g) and hydrazine hydrate (0.1 mol, 5 g) were mixed gently and heated under reflux for 4 hrs. With 100 ml of absolute ethanol [15]. The crude product was filtered and washed with ethanol to give the desired product (C). A mixture of C (0.1mol, 7g) and (0.1 mol, 5.7g) of potassium hydroxide with 100 ml from ethanol was heated until potassium hydroxide dissolved. Then the mixture was cooled at 0 Co, then (0.1 mol, 6.5ml) from carbon disulphide was added. The mixture was heated under reflux for 24 hrs. The resultant mixture was concentrated, and carefully acidified with hydrochloric acid HCl (10%) to give yellow precipitate.

Then the crude product was filtered and the crystal was recrystallized from ethanol absolute [16] to give the product (D) as yellow solid, (yield 74%). A mixture D (0.1mol, 11.6 g) (and hydrazine hydrate (0.1 mol, 5g) dissolved in (50 ml) of ethanol and reflux for (19 hrs.). The crude product was concentrated and then cooled [17] Solid product was filtered and recrystallized from ethanol to give the product (E) as yellow solid, yield (80%). Synthesis L2 was started with (0.01 mol, 1.51 g) para naitro-benzldehyd, which was mixed with 15 ml ethanol. After this (0.02 mol, 2.24 g) of compound E was added to this alcoholic solution. Mixture was allowed to reflux for 5 hours. Product was filtered, and recrystallized from ethanol, yield 88% as the Scheme (1).

Scheme 1: steps to prepared 1, 3, 4-oxadiazole derivative (L2)

#### **Preparation Method of Complexes**

All complexes were prepared by refluxing the respective hydrated metal chloride (0.001mol) in 15 ml ethanol with 50 ml of an

ethanolic solution of ligand (0.001 mol) for 3 hrs. The separated solids were filtered and washed with ethanol and cold water to remove unreacted salts or ligand, then precipitated complexes dried in air [18].

Table 1: Molecular formula and some physical properties of prepared complexes

| NO. | Formula              | M.Wt  | Color        | M.P.°C  | Yield% |
|-----|----------------------|-------|--------------|---------|--------|
| 1   | L2                   | 247   | Light yellow | 214-216 | 88.5   |
| 2   | $[Cr(L_2) Cl_3H_2O]$ | 423   | Orange       | 187-188 | 75.4   |
| 3   | $[Co(L_2) Cl_2]$     | 376   | Olive        | 193-195 | 76.3   |
| 4   | $[Cu(L_2) Cl_2]$     | 381.5 | Brown        | 204-205 | 83.1   |
| 5   | $[Ni(L_2) Cl_2]$     | 376.6 | Light green  | 175-177 | 88.4   |

## **Biological Study**

## **Antibacterial Activity**

Antibacerial activity of the prepared ligand and its complexes was studied, three types of bacteria were used, *Staphylococcus aureus*, *Streptococcus pyogenes* and *Enterobacter aerogenes*.

These species have been selected because of their importance in the medical field as they cause multiple types of diseases. The method which used to calculate the inhibitory effect of chemical compounds was Disc Diffusion method [19, 20].

- Prepare Muller Hinton agar plates according to the manufacture instructions.
- Make refreshment for bacterial isolates by incubated in nutrient broth at 37 °C overnight.
- Different concentrations of the ligand and its complexes were prepared using diluted DMSO as solvent.
- Filter paper discs were prepared and soaked in the solutions of the ligand and its complexes overnight.
- A lawn of bacteria was made by sterile swab on the Muller Hinton agar plates then soaked filter paper discs put on the plates with use two types of control, negative control (filter paper disc soaked in diluted DMSO) and positive control (antibiotic disc). The plates incubated at 37 °C for 24 hrs.
- Inhibition zone on the plated measured in mm unit.

#### Hemolysis Assay

The Hemolysis assay was done as described by Henkelman.S. Et al [21].5mL of blood was collected from healthy volunteers (exclusion criteria include the volunteers not have bleeding disorder) in the tubes containing 5.4 mg of EDTA to prevent coagulation and centrifuged at 1000 rpm for 10 min at 4C. Plasma was removed carefully and the white buffy layer was completely removed by aspiration with a pipette with utmost care. The erythrocytes were then washed for additional three times with 1X PBS, pH 7.4 for 5 min. Washed erythrocytes were stored at 4oC and used within 6 h for the hemolysis assay.

50 uL of 10 dilution (100 uL Erythrocytes suspension: 900 uL 1XPBS) of erythrocytes suspension was mixed with 100 uL of test samples (20-80ng/mL), 100 uL of 1XPBS was used as negative control and 100 uL of 1% SDS as positive controls. Reaction mixture was incubated at 370C water bath for 60 min. The volume of reaction mixture was made upto 1 mL by adding 850 uL of 1XPB. Finally it was centrifuged at 300rpm for 3min and the resulting hemoglobin in supernatant was measured at 540 nm by spectrophotometer to determine concentration of hemoglobin. The percentage hemolysis was calculated as follows

% Hemolysis inhibition= 100-[Sample/Control] x 100.

#### **Experimental Section**

Infrared absorption spectra were recorded on FTIR spectrophotometer on a model (Shimadzu FT-IR Spectrometer) in the range (200-4000) cm<sup>-1</sup> using KBr and CsI disks. <sup>1</sup>H-NMR spectra were recorded at 500 MHZ utilize a model Bruker DRX, TMS was use as standard, DMSO-d<sup>6</sup> used as solvent. Mass spectra (MS) were registered in the range (0-800) m/e on 5973 network mass selective detector. Elemental C, H, N and S analysis were carried out on analyzer 2400 Perkin Elmer.

Melting points were recorded in open capillary tubes using an electro thermal melting point/SMP31 device.

# Result and Discussion Elemental Analysis

The purity of 2-methyl-5-[(2E)-2-(4-nitrobenzylidene)hydrazinyl]-1,3,4-oxadiazol and its complexes were checked by TLC .Elemental analysis (C, H, N) tabulated in Table (2).The theoretical values were in a good accordance with the experimental values.

Table 2: Elemental analysis (C, H, N)

| Compound | Elemental analysis theoretical l |       |       | Elemental a | nalysis Experiment | al l |
|----------|----------------------------------|-------|-------|-------------|--------------------|------|
|          | Н%                               | С%    | N%    | Н%          | С%                 | N%   |
| $L_2$    | 3.6                              | 48.58 | 28.34 | 4.2         | 49.1               | 27.4 |

## FTIR Spectra of L2 and its Complexes

The structure of the prepared ligand (L2) and its metal complexes were confirmed by infrared spectroscopy. The characteristic bands are shown in the Table (3). The infrared spectrum of the ligand (L2) show band at (v 3465) cm-1 indicating the absorption for v (NH) [22]. The ligand also shows the presence six major bands at (3070, 2954, 1680, 1581, 1103 and 1030) cm-1 which are assigned to (v CH (aromatic), CH

(Aliphatic), CH=N (aso), C=N (endocyclic) (Cand structure movement band respectively. New bands were found attributed to coordinate (v M-N and M-Cl) these appear at region (509-586) and (239-285) cm<sup>-1</sup> respectively [23, 24], and (M-O) at (401) cm<sup>-1</sup> this indicate that the coordination occur through N and O atoms only. Moreover the bands stretching showed shifted to higher lower value. this indicates coordination with metal ion as show the Table (3) and The Figures (1-5).

Table 3: FT-IR absorption bands of the prepared L2 and their complexes

| NO. | Compoud                                     | uNH<br>cm-1 | CH-<br>aliphtic | uCH-<br>aromatic<br>cm <sup>-1</sup> | uC=N<br>endo<br>cm-1 | uCH=N<br>cm <sup>-1</sup> | uC-<br>Ocm <sup>-1</sup> | Structural<br>movement<br>cm <sup>-1</sup> | uM-O<br>cm-1 | uM-N<br>cm <sup>-1</sup> | uM-<br>Cl<br>cm <sup>-1</sup> |
|-----|---|-------------|-----------------|--------------------------------------|----------------------|---------------------------|--------------------------|--|--------------|--------------------------|-------------------------------|
| 1   | L2  | 3465        | 2954            | 3070                                 | 1581                 | 1680                      | 1103)                    | 1030                                       |              |                          |                               |
| 2   | [Cr(L2)Cl <sub>3</sub> H <sub>2</sub><br>O] | 3209        | 2971            | 3109                                 | 1527                 | 1604                      | 1103                     | 1033                                       | 401          | 586                      | 270                           |
| 3   | $[\mathrm{Co}(\mathrm{L2})\mathrm{Cl}_2]$   | 3400        | 2931            | 3109                                 | 1589                 | 1697                      | 1113                     | 1030                                       |              | 529                      | 285                           |
| 4   | [Cu(L2)Cl <sub>2</sub> ]                    | 3348        | 2924            | 3070                                 | 1589                 | 1690                      | 1103                     | 1025                                       |              | 555                      | 250                           |
| 5   | [Ni(L2)Cl <sub>2</sub> ]                    | 3340        | 2931            | 3062                                 | 1597                 | 1689                      | 1103                     | 1025                                       |              | 509                      | 239                           |




Figure 1: FTIR Spectrum of (L2)




Figure 2: FTIR Spectrum of [Co (L2)  $Cl_2$ ]




Figure 3: FTIR Spectrum of [Cu (L2) Cl2]




Figure 4: FTIR Spectrum of [Ni (L2) Cl2]




Figure 5: FTIR Spectrum of [Cr (L2)  $Cl_3H_2O$ ]

Nuclear Magnetic Resonance Spectra Study of L2 (<sup>1</sup>H-NMR) 1H NMR spectrum of ligand shows the signals (ppm) at 2.5(s, 3H, CH<sub>3</sub>), 8.2-8.4 (4H, Ar-H), 10.4 (s, 1H, N=CH) [25], 11.9 (s, 1H, NH) [26], Figure (6).




Figure 6: ¹HNMR Spectrum of L2


## Mass Spectrum of L2

Mass spectrum of ligand shows the molecular ion peak at 247 m/z, base peak at 115m/z and

other peaks list in Table (4) which confirms the structural formula of L2As in the following Scheme (2) Figure (7).

Table 4: Proposed nuts for ligand (L2)

| Molecular  | m/z | Molecular          | m/z |
|--|-----|--------------------|-----|
| $[C_{10}H_9N_5O_3]^{+}$  | 247 | $[C_7H_7NO_2]^{+}$ | 137 |
| $[C_9H_6N_5O_3]^{+}$   | 233 | $[C_3H_6N_4O]^{+}$ | 115 |
| $[C_{10}H_9N_4O]^{+}$  | 205 | $[C_7H_6N]^{+}$    | 102 |
| $[C_8H_7N_3O_3]^{+}$   | 193 | $[C_7H_6]^{+}$     | 89  |
| $[C_7H_6N_3O_2]^{+}$   | 165 | $[C_6H_6]^{+}$     | 77  |
| [C <sub>7</sub> H <sub>2</sub> N <sub>2</sub> O <sub>2</sub> ]+. | 149 |                    |     |



Scheme 2: Proposed fragments of L2

File :C:\MSDCHEM\1\DATA\1397\DIRECT PROB\_015975.D\Snapshot\DIRECT

... PROB\_016023.d

Operator :

Instrument: Direct Prob

Acquired : 12 Aug 2018 10:01 using AcqMethod Normal.M

Sample Name: L2Z Misc Info :




Figure 7: Mass spectra of L2

## Mass Spectrum of Complex [Ni(L2)Cl2]

Mass spectrum of complex appearance of the

molecular ion peak at 376~m/z, the spectrum showed other peaks (Figure 8) list in Table (5).

Table 5: Proposed nuts for [Ni(L2)Cl2]+.

| NO. | Molecular                  | m/z   |
|-----|----------------------------|-------|
| 1   | [Ni(L2)Cl <sub>2</sub> ]+· | 376.4 |
| 2   | [Ni(L2)Cl]+                | 341.3 |
| 3   | [Ni(L2)]+.                 | 305.2 |
| 4   | $[C_{10}H_0N_5O_2]^+$      | 247.2 |

File :C:\MSDCHEM\1\DATA\1397\DIRECT PROB 015975.D\Snapshot\DIRECT

... PROB 016034.d

Operator :

Instrument : Direct Prob

Acquired : 12 Aug 2018 12:19 using AcqMethod Normal.M

Sample Name: M5Z Misc Info :




Figure 8: Mass spectra of [Ni (L2) Cl2]

# Mass Spectrum of Complex [Cu (L2) $Cl_2$ ]

 $Mass\ spectrum\ of\ complex\ appearance\ of\ the$ 

molecular ion peak at 381.5m/z, the spectrum showed other peaks (Figure 9) list in Table (6).

Table 6: proposed nuts for [Cu (L2) Cl2] +

| NO. | Molecular                  | m/z   |
|-----|----------------------------|-------|
| 1   | [Cu(L2)Cl <sub>2</sub> ]+. | 381.5 |
| 2   | [Cu(L2)Cl]+·               | 346.4 |
| 3   | [Cu(L2)]+·                 | 310.5 |
| 4   | $[C_{10}H_9N_5O_3]^{+}$    | 247   |

File :C:\MSDCHEM\1\DATA\1397\DIRECT PROB\_015975.D\Snapshot\DIRECT

... PROB 016033.d

Operator :

Instrument : Direct Prob

Acquired : 12 Aug 2018 12:01 using AcqMethod Normal.M

Sample Name: M6Z Misc Info :




Figure 9: Mass spectra of [Cu(L2) Cl2]


## Mass Spectrum of Complex [Co(L2)Cl2]

Mass spectrum of complex appearance of the molecular ion peak at 376.5 m/z, the

spectrum showed other peaks (Figure 10) list in Table (7).

Table 7: Proposed nuts for [Co (L2) Cl2] +.

| NO. | Molecular                              | m/z   |
|-----|--|-------|
| 1   | [Co(L2)Cl <sub>2</sub> ] <sup>+.</sup> | 376.5 |
| 2   | [Co(L2)Cl]+·                           | 341.2 |
| 3   | [Co(L2)]+·                             | 306.2 |
| 4   | $[C_{10}H_9N_5O_3]^+$                  | 247.3 |



File :C:\MSDCHEM\1\DATA\1397\DIRECT PROB\_015975.D\Snapshot\DIRECT

... PROB 016033.d

Operator :

Instrument : Direct Prob

Acquired : 12 Aug 2018 12:01 using AcqMethod Normal.M

Sample Name: M7Z Misc Info :




Figure 10: Mass spectra of [Co (L2)  $\mathrm{Cl_2}$ ]


# Mass Spectrum of Complex [Cr (L2) $Cl_3H_2O$ ]

spectrum showed other peaks (Figure 11) list in table.

Mass spectrum of complex appearance of the molecular ion peak at 423.4 m/z, the

Table 8 proposed nuts for [Cr (L2) Cl<sub>3</sub>H<sub>2</sub>O] +.

| Tubic o proposed mass | [ ()0   |       |
|-----------------------|---|-------|
| NO.                   | Molecular   | m/z   |
| 1                     | $[\mathrm{Cr}(\mathrm{L2})\mathrm{Cl_3H_2O}]^{+}$                   | 423.3 |
| 2                     | $[\operatorname{Cr}(\operatorname{L2})\operatorname{Cl}_3]^{+}$     | 405.4 |
| 3                     | $[\operatorname{Cr}(\operatorname{L2})\operatorname{Cl}_2]^{+}$     | 369.9 |
| 4                     | $[\operatorname{Cr}(\operatorname{L1})\operatorname{Cl}]^{+}$       | 334.4 |
| 5                     | $[\operatorname{Cr}(\operatorname{L1})]^+$                          | 298.1 |
| 6                     | $[\mathrm{C}_{10}\mathrm{H}_{9}\mathrm{N}_{5}\mathrm{O}_{3}]^{+}$ . | 247   |



File ;C:\MSDCHEM\1\DATA\1397\DIRECT PROB 015975.D\Snapshot\DIRECT

... PROB\_016034.d

Operator :

Instrument : Direct Prob

Acquired : 12 Aug 2018 12:19 using AcqMethod Normal.M

Sample Name: M8Z Misc Info :




Figure 11: Mass spectra of [Cr (L2) Cl<sub>3</sub> H<sub>2</sub>O]

#### Theoretical Study of L2

The free ligands (L1) and its complexes with transition metal ions (Cr<sup>+3</sup>, Cu<sup>+2</sup>, Co<sup>+2</sup>, Ni<sup>+2</sup>) have been studied theoretically to predict the most stable structure among others. The program Hyperchem 7.51 have been used for

theoretical calculation using PM3 method to study the electrostatic potential, electron density, heat of formation, heat of complexation, binding energy, symmetry and other geometrical parameters as shown the Figure (12).




Figure 12: L1 and electrostatic potential

# Biological Study Antibacterial Effect

The L2 showed high inhibition zone (16 mm) at concentration 1.2 mg/ml against *Enterobacter aerogenes* and showed 11 mm

and 8 mm against *Streptococcus pyogenes* and *Staphylococcus aureus* respectively. The complexes of the ligand also showed highest inhibition zone at concentration 1.2 mg/ml with variable effect of bacterial isolates, for

example [Ni (L2) Cl<sub>2</sub>] and [Co (L2) Cl<sub>2</sub>] express 12 and 17 mm inhibition zone against *Staphylococcus aureus* respectively, [Cu (L2) Cl<sub>2</sub>] showed highest inhibition zone 12 mm against *Enterobacter aerogenes* while [

and its complexes with different concentrations against three species of bacteria.

Cr (L2) Cl<sub>3</sub> H<sub>2</sub>O] showed same inhibition zone 11 mm against both *Enterobacter aerogenes* and *Staphylococcus aureus* Figure (13). Table




Figure 13: Effect of Ligand and its complexes against three species of bacteria

Table 9: The effect of the ligand and its complexes with different concentrations against three species of bacteria

| Compound                                 | Concentration |                           | Inhibition Zone (mm)  |                           |
|--|---------------|---------------------------|-----------------------|---------------------------|
|  | mg/ml         | Streptococcus<br>pyogenes | Staphylococcus aureus | Enterobacter<br>aerogenes |
| L2                                       | 1.2           | 11                        | 8                     | 16                        |
| L2                                       | 0.62          | 10                        | 8                     | 11                        |
| L2                                       | 0.31          | 10                        | No inhibition         | 10                        |
| L2                                       | 0.15          | 10                        | No inhibition         | 10                        |
| Antibiotic                               |               | 30                        | 28                    | 20                        |
| [Ni(L2)Cl <sub>2</sub> ]                 | 1.2           | 8                         | 12                    | 9                         |
| [Ni(L2)Cl <sub>2</sub> ]                 | 0.62          | 8                         | 10                    | 9                         |
| $[Ni(L2)Cl_2]$                           | 0.31          | 8                         | 10                    | 9                         |
| [Ni(L2)Cl <sub>2</sub> ]                 | 0.15          | 8                         | No inhibition         | 9                         |
| Antibiotic                               |               | 28                        | 25                    | 15                        |
| $[Co(L2)Cl_2]$                           | 1.2           | 8                         | 17                    | 8                         |
| $[Co(L2)Cl_2]$                           | 0.62          | 8                         | 11                    | 8                         |
| $[Co(L2)Cl_2]$                           | 0.31          | 8                         | 9                     | No inhibition             |
| $[Co(L2)Cl_2]$                           | 0.15          | 7                         | 8                     | No inhibition             |
| Antibiotic                               |               | 28                        | 20                    | 20                        |
| $[Cu(L2)Cl_2]$                           | 1.2           | 10                        | 8                     | 12                        |
| $[Cu(L2)Cl_2]$                           | 0.62          | 8                         | 8                     | No inhibition             |
| $[Cu(L2)Cl_2]$                           | 0.31          | No inhibition             | 8                     | No inhibition             |
| $[Cu(L2)Cl_2]$                           | 0.15          | No inhibition             | No inhibition         | No inhibition             |
| Antibiotic                               |               | 27                        | 15                    | 18                        |
| $[Cr(L2)Cl_3H_2O]$                       | 1.2           | 8                         | 11                    | 11                        |
| $[Cr(L2)Cl_3H_2O]$                       | 0.62          | 8                         | 8                     | 10                        |
| [Cr(L2)Cl <sub>3</sub> H <sub>2</sub> O] | 0.31          | No inhibition             | 8                     | 10                        |

| [Cr(L2)Cl <sub>3</sub> H <sub>2</sub> O] | 0.15 | No inhibition | 7  | 10 |
|--|------|---------------|----|----|
| Antibiotic                               |      | 23            | 24 | 20 |

## Hemolysis

The results showed there was high percentage of hemolysis ranged between 55% to 81 % regardless of concentration of the compounds (Table 10) and this indicate to the strong effect of these compounds on human RBC leading to destruction of these RBC. These results need to more studies on the molecular level to investigate the level of

effect of these compounds on the cell membrane of RBC and trying to find solution in the chemical design of these compounds to treat this issue of hemolysis. On the other hand, this compound could be used as antibacterial agents especially for these bacteria that known as multidrug resistant even with the presence of hemolysis because the issue of hemolysis could be override by blood transfusion.

Table 10: hemolysis percentages of ligand (L2) and its complexes

| Compound                                  | mg/ml Concentration | Hemolysis% |
|---|---------------------|------------|
| L2  | 0.2                 | 68.69      |
| L2  | 0.1                 | 61.73      |
| L2  | 0.05                | 55.90      |
| [Ni(L2)Cl <sub>2</sub> ]                  | 0.2                 | 81.57      |
| [Ni(L2)Cl <sub>2</sub> ]                  | 0.1                 | 74.67      |
| [Ni(L2)Cl <sub>2</sub> ]                  | 0.05                | 72.74      |
| $[Co(L2)Cl_2]$                            | 0.2                 | 68.11      |
| $[Co(L2)Cl_2]$                            | 0.1                 | 58.38      |
| $[\mathrm{Cu}(\mathrm{L2})\mathrm{Cl_2}]$ | 0.1                 | 67.90      |
| $[\mathrm{Cu}(\mathrm{L2})\mathrm{Cl_2}]$ | 0.05                | 60.45      |
| $[\mathrm{Cu}(\mathrm{L2})\mathrm{Cl_2}]$ | 0.025               | 58.17      |
| $[Cr(L2)Cl_3H_2O]$                        | 0.2                 | 63.97      |
| $[Cr(L2)Cl_3H_2O]$                        | 0.1                 | 62.93      |
| $[Cr(L2)Cl_3H_2O]$                        | 0.025               | 57.97      |

#### References

- 1. LA Paquette, Translated by FA Hussein, HK Awadhi, SS Al-Azawi (1989) "principle of modern hetrocyclic chemistry", Higher Education press, Baghdad.7.
- 2. AR Kartizky (2013) "Comprehensive Hetrocyclic Chemistry", J. chem. Inf. Model., 53(9): 1689-1699.
- 3. YJ Ahmed (2012) "Biological Activity & Some Transition Elements Complexes for 1, 3, 4 Oxadiazole Derivatives on Growth of Some Pathogenic Bacteria", 7: 1.
- 4. Brian ST, et al (1989) "Vogel's: Practical Organic Chemistry", 5ed. Longman Scientific Technical, New York, 1077.
- 5. DT Davies (1997) "Aromatic heterocyclic chemistry", De Boeck Sup {é} rieur.
- 6. B Mukesh, et al (2011) "biological activites Of 1, 3, 4-Oxadiazole: A review ", 2 (12): 84-89.
- 7. F Priya V Balakrishna Kalluraya (2005) "Synthesis of 1, 3, 4-oxadiazoles carrying imidazole moiety".

- 8. Husain À Ahmad, MM Alam, M Ajmal, P Ahuja (2009) "Synthesis and Biological evaluation of am utual prodrug of norfloxacin and fenbufen", Eur. J. Med. Chem., 44: 3798-3804.
- 9. MM Burbuliene, et al (2004) "Synthesis and anti-inflammatory activity of derivatives of 5-[(2-disubstitutedamino-6-methyl-pyrimidin-4-yl)-sulfanylmethyl]-3H-1, 3, 4-oxadiazole-2-thiones", Farm., 59 (10): 767-774.
- 10. Z Li, P Zhan, X Liu (2011) "1, 3, 4-oxadiazole: aprivileged structure in antiviral agent", Rev. Med. Chem., 11: 1130-1142.
- 11. MSR Murty, et al (2013) "Synthesis of piperazinyl benzothiazole / benzoxazole derivatives coupled with 1, 3, 4-oxadiazole-2-thiol: novel hybrid heterocycles as anticancer agents." Medicinal Chemistry Research, 22 (10): 4980-4991.
- 12. Ilangovan, et al (2015) "T3P as an efficient cyclodehydration reagent for the one-pot synthesis of 2-amino-1, 3, 4-oxadiazoles",

- Journal of Chemical Sciences, 127 (5): 797-801.
- 13. Zarghi Afshin, et al (2005) "Synthesis and anticonvulsant activity of new 2-substituted-5-(2-benzyloxyphenyl)-1, 3, 4-oxadiazoles." Bioorganic& medicina chemistry letters, 15 (7): 1863-1865.
- 14. À Savarino (2006) "A historical sketch of the discovary and development of HIV-1 integrase inhibitors", Expert Opin. Drugs, 15: 1507-1522.
- 15. Z Khiati, et al (2007) "Synthesis and Antibacterial Activity of 1, 3, 4-Oxadiazole and 1, 2, 4-Triazole Derivatives of Salicylic Acid and its Synthetic Intermediates", 20-24.
- 16. MY Hayal (2014) "Syntheses, Characterization and Antimicrobial Studies of a New Complex with Some Transition Metal", 9 (1): 1-10.
- 17. OS Moustafa, et al (2002) " New fused quinoxalines: Synthesis and reactions of pyrimidothienoquinoxaline and oxadizolylthienoqui noxalines", Bull. Korean Chem. Soc., 23(4): 567-570.
- AS 18. A Μ Al-Agez, Fouda (2009)"Phenylhydrazone derivatives as M. corrosion inhibitors for -α-brass in hydrochloric acid solutions," International Journal of Electrochemical Science, 4: 336-352.
- 19. BM Abubakar, À Abubaker (2017) "An appraisal on antibiotic susceptibility of common bacterial pathogens in urinary tract infection at a Nigerian tertiary health center", U.M. Tela, Archives of International Surgery, 7: 56-61.
- 20. SR Hussain, BS Almugadam (2018) "Prevalence of symptomatic urinary tract infection and antimicrobial susceptibility patter ns of isolated uropathogens in kohat region of Pakistan", Mot Viol. Med., 3: 85-89.

- 21. S Vinjamuri, D Shanker (2015) "In vitro evaluation of hemdytic activity and cell viability assay of hexanoic extracts of bridelia ferraginea benth", World Journal of pharmacy and pharmaceutical sciences, 4: 1263-1268.
- 22. MS Jabir, AA Taha, UI Sahib (2019) "Novel of nano delivery system for linaloof loaded on gold nanoparticles Conjugated with CALNN peptide for application in drug uptake and inducation of cell death on breast cancer cell line", Materials Science and engineering, 94: 949-964.
- 23. K Laskar (2016) "Synthesis, characterization and interaction studies of 1, 3, 4-oxadiazole derivativesof fatty acid with human serum albumin (HAS): A combined multi-spectroscopic and molecular docking study"Eur. J. Med. Chem., 122: 72-78.
- 24. AA Khaudar, Rezvani (1998) "Preparation and thermal properties of the bis [5-((4-heptyloxyphenyl)) azo)-N-(4-alkoxyphenyl)-Salicylaldiminato] Copper (II) Complex homologues fnl", polyhedron, 18 (1-2): 129-133.
- 25. EH Shwail (2018) M.Sc. Thesis, Thi-Qar University.
- 26. S Abdul-Kareem (2016) "Synthesis of some new Schiff bases and reaction with urea &thiouvea derivatives from 2-amino-1, 3, 4-thiadiazole -5-thiol" J. of college of basic education, 94 (22): 33-46.